NICE recommends Janssen psoriasis drug that showed superiority to Humira

2 May 2018

The National Institute for Health and Care Excellence (NICE) has issued a final appraisal determination (FAD) recommending that Tremfya (guselkumab) be provided on the UK’s National Health Service (NHS) for patients with moderate to severe plaque psoriasis.

As part of the fast track appraisal procedure, the NICE issued a FAD rather than an appraisal consultation document, speeding up the process by which eligible patients are able to access the drug, which is the first biologic to selectively target interleukin (IL)-23, a key protein involved in the immune inflammatory response in psoriasis.

The NICE FAD was fast-tracked following European Commission approval in November last year, based on the Phase III trials, VOYAGE 1 and VOYAGE 2. These compared the Janssen treatment with placebo and the big-selling AbbVie (NYSE: ABBV) drug Humira (adalimumab).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK